Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Opdivo drug end of patent?Whennwas crestor. made?When will mepolizumab lose patent status?Opdivo nivolumab patent expiration worldwide us eu china india brazil 2028 2029 2030 biosimilar?Erleada clinical trial summaries providers?
See the DrugPatentWatch profile for bosulif
Bosulif is a brand name (often written as “Bosulif” in prescriptions). The generic name is bosutinib (marketed as bosutinib tablets).
If you mean the FDA’s list of generic names (or typical “generic name” listings used by pharmacies), Bosulif would appear there under bosutinib, not as “Bosulif.”
In standard drug naming, Bosulif is not the generic name. It is the branded product name, while bosutinib is the active ingredient name used as the generic name.
Other Questions About Bosulif :